Janssen Presents P-III (UNIFI) Study Results of Stelara (ustekinumab) for Active Ulcerative Colitis at UEG 2022
Shots:
- The P-III (UNIFI) study evaluating Stelara (90mg, q8w or q12w, IV) as induction & maintenance in adult patients with active UC
- The results showed that induction responder patients treated with Stelara at the start of maintenance were in symptomatic remission (55.2% @200wks. vs 64.9% @44wks.) while in biologic-naïve patients (67.2% @200wk. vs 71.8% @44wks.), 72.9% in clinical remission @44wk. were also in symptomatic remission @200wk., safety event rates were similar with no new safety signals
- 79.1% of patients LTE who received corticosteroids at maintenance baseline no longer received corticosteroids by 200wk., rates of corticosteroid-free symptomatic remission @200wk. were similar b/w q8w (63.6%) & q12w (66.7%); corticosteroid-free (94.8% vs 97.9%)
Ref: Janssen | Image: Janssen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
